Imfinzi recommended for rNSCLC

6 December 2024

Imfinzi (durvalumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with resectable non-small cell lung cancer (rNSCLC) for National Health Service (NHS) use in England and Wales.

This decision from NICE is based on positive results from the AEGEAN Phase III trial, and means that the AstraZeneca (LSE: AZN) immunotherapy drug is now available in both resectable and unresectable NSCLC settings in these nations.

John Conibear, clinical director of thoracic oncology at Barts Cancer Centre, said: “Patients with NSCLC continue to face unacceptably high rates of disease recurrence within five years of surgery, highlighting the need for a comprehensive treatment approach that integrates surgery with systemic therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK